New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • Could gold be the key to making gene therapy for HIV, blood disorders more accessible?

    Could gold be the key to making gene therapy for HIV, blood disorders more accessible?  Scientists at Fred Hutchinson Cancer Research Center took a step toward making gene therapy more practical by simplifying the way gene-editing instructions are delivered to cells. Using a gold nanoparticle instead of an inactivated virus, they safely delivered gene-editing tools in lab models of HIV and inherited blood disorders, as reported May 27 in Nature Materials.

    28 May 2019 |
  • CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA

    After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA. Trial will include 10 weeks of induction therapy to identify which patients are likely to respond and which patients can safely return to their original HAART regimen.

    17 May 2019 | CytoDyn press release
  • NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

    A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.

    09 May 2019 | National Institute of Allergy and Infectious Diseases
  • ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

    If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV

    29 April 2019 | ViiV press release
  • ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

    Recommendation based on landmark GEMINI 1 & 2 studies which demonstrated non-inferior efficacy of dolutegravir + lamivudine compared to a traditional dolutegravir-based, three-drug regimen, in HIV-1 infected, treatment-naïve adults.

    26 April 2019 | ViiV press release
  • Gilead's first big TV push for triple combo Biktarvy showcases HIV diversity

    Gilead Sciences wanted to represent the wide range of people living with HIV in its first national TV campaign for Biktarvy. So they chose black, Latino, male, female, gay, bisexual and transgender actors for an ad that encourages people with HIV to “keep being you.”

    18 April 2019 | FiercePharma
  • Novel Antibody May Suppress HIV for Up to Four Months

    Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine.

    18 April 2019 | NIAID
  • Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment?

    When HIV drugmaker ViiV announced in late 2017 that it had received Food and Drug Administration (FDA) approval for Juluca (dolutegravir/rilpivirine), the first effective two-drug, single-pill HIV regimen in the modern treatment era, community activists hoped that its price would reflect the fact that it contained one drug fewer than three-drug tablets like Complera (rilpivirine/tenofovir disoproxil fumarate/FTC), Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), Stribild (cobicistat/elvitegravir/FTC/tenofovir disoproxil fumarate), and Triumeq (abacavir/dolutegravir/lamivudine), all of which are generally priced between $2,600 and $3,500 a month in the U.S.

    15 April 2019 | The Body
  • FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

    The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.

    09 April 2019 | Food & Drug Administration
  • HIV Drugs With Fewer Side Effects Need More FDA Support

    New medicines providing a better quality of life should always be top priority when asking for federal support.

    27 March 2019 |
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.